Key Points to Remember GLP-1 receptor agonists are powerful tools for managing type 2 diabetes and supporting weight loss
This fundamental shift explains why many users describe the experience as effortless compared to previous weight loss attempts
The glucagon receptor activation unique to Retatrutide does not appear to add thyroid risk
The mechanism of action includes several key effects: Stimulating insulin secretion from the pancreas in a glucose-dependent manner, helping to control blood sugar levels Slowing gastric emptying , which prolongs the feeling of fullness after meals Reducing appetite through effects on brain centres that regulate hunger Decreasing glucagon secretion , which helps prevent excessive glucose production by the liver By targeting these multiple pathways, GLP-1 medications can lead to significant weight loss when combined with lifestyle modifications
This finding indicates that exendin 2029 does not activate GLP-1R (Supplementary Fig
That triple agonism is generating intense interest in pre-clinical metabolic-research circles, where investigators are comparing it head-to-head against the dual agonist Tirzepatide and the GLP-1 mono-agonist Semaglutide